Introduction: Osteosarcoma is the most common primary malignant bone tumor and has a high rate of systemic spread especially to the lungs. Approximately 14% of the patients have lung metastases at diagnosis. Primary metastasis is one of the risk factors, and increases mortality rate. Moreover, multidrug combination chemotherapy for osteosarcoma entails ototoxicity, cardiac toxicity, and secondary malignancies. To resolve these problems, new molecular targeting therapy with high tumor specificity is expected. Podoplanin (PDPN/Aggrus), a platelet aggregation-inducing typeI transmembrane sialoglycoprotein, is involved in tumor invasion and metastasis (1). By contrast, podoplanin is also useful as a selective marker of lymphatic endothelium (2). Several studies have reported that osteosarcoma tissues and cell lines such HOS, U-2 OS, and MG63 express high levels of podoplanin. Moreover, podoplanin expression was reported to be involved in poor prognosis of osteosarcoma patients (3). However, the association between podoplanin expression and metastasis of osteosarcoma remains to be clarified because of the lack of high-sensitive anti-podoplanin monoclonal antibodies (mAbs), although many anti-podoplanin mAbs such as NZ-1 and D2-40 have been established. In this study, we established a novel anti-podoplanin mAb, LpMab-7, which possesses high sensitivity against podoplanin. Using LpMab-7, we investigated podoplanin expression in primary and metastatic lesions of osteosarcomas. Methods: Hybridoma production BALB/c mice were immunized by i.p. injection of 1 × 108 LN229/hPDPN cells. After several additional immunizations with 1 × 108 LN229/hPDPN cells, a booster injection was given i.p. 2 days before spleen cells were harvested. The spleen cells were fused with mouse myeloma P3U1 cells. The hybridomas were grown in RPMI medium with hypoxanthine, aminopterin, and thymidine selection medium supplement. The culture supernatants were screened using ELISA for binding to recombinant human podoplanin purified from LN229/hPDPN cells. Epitope mapping using ELISA, Western-blot, and flow cytometry To determine the epitope of LpMab-7, ELISA was performed for synthetic peptides of podoplanin. Several point mutants of podoplanin were produced and detected using Western blotting and flow cytometry. Immunohistochemistry (IHC) against osteosarcoma tissues Tissue specimens from 16 osteosarcoma patients, who underwent surgery at University Hospital of our institute, were used for IHC using LpMab-7, NZ-1, and D2-40. Four pulmonary metastatic specimens were used for additional studies. The study was approved by the institutional ethical committee.
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